Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Details
Category: Globe NewsWire News Distribution Service

Media Release COPENHAGEN, Denmark; December 7, 2024 Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, plus lenalidomide + rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The results demonstrated an overall response rate…


Posted: 2024-12-08 00:12:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | investigational | epcoritamab | duobody®


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Newscast

AbbVie announces updated results from Phase 1b/2 EPCORE NHL-2 trial

Sun, 08 Dec 2024 07:57:00 GMT AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab ... moving breaking financial news. Try Now>> See the top ...

AbbVie announces updated results from Phase 1b/2 EPCORE NHL-2 trial

Sun, 08 Dec 2024 04:10:00 GMT AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered ...

AbbVie: Epcoritamab Combo Shows High Response Rates In R/R Follicular Lymphoma Trial

Sat, 07 Dec 2024 17:40:00 GMT (RTTNews) - AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab ... For More Such Health News, visit rttnews.com.

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Wed, 02 Nov 2022 23:01:00 GMT Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines ... the safety and efficacy of epcoritamab (DuoBody ®-CD3xCD20), an investigational ...




Blow Us A Whistle